We are proud to have shared the platform twice this week at Cell & Gene Therapy World Asia Congress 2026, held 30 June – 1 July at the Sands Expo & Convention Centre, Singapore — one of Asia’s leading congresses for advanced therapeutics.
Two members of the Biosceptre leadership team took the stage to showcase both the clinical promise and the underlying molecular design of the BRiDGECAR™ platform, reinforcing the breadth of expertise driving the programme forward.
Mr Gavin Currie: “One CAR-T, Empowering Clinical Choice: The BRiDGECAR™ Platform”
- One cell, multiple targets
- Controlled & adjustable activity
- Expanding beyond traditional CAR-T applications
Date: Tuesday 30 June 2026 @ 9:40am (SGT)
Ms Cindy Li, Director of R&D, Biosceptre International, Australia: “Architecture of Control: The Molecular Design Behind BRiDGECAR™”
- Modular by design
- Adaptor-gated activation
- Platform potentials
Date: Wednesday 1 July 2026 @ 11:00am (SGT)
Together, these two presentations gave the international CGT community a complete picture of BRiDGECAR™ — from the clinical flexibility it offers physicians through to the precision engineering that makes it possible — underscoring the platform’s readiness for the next phase of growth.
